Pfizer Finalizes $2.3B Bextra Off-Label Marketing Deal

Law360, New York (September 2, 2009, 5:13 PM EDT) -- Pfizer Inc. will pay $2.3 billion and one of its subsidiaries will plead guilty to a criminal charge to settle claims that the drug giant improperly marketed the discontinued anti-inflammatory drug Bextra and three other medicines, federal regulators announced Wednesday, marking the largest such settlement on record.

Pfizer first reported that it had reached the settlement in principle in a January filing with the U.S. Securities and Exchange Commission.

One unit of Pfizer, Pharmacia & Upjohn Company Inc., agreed to plead guilty to one criminal count...
To view the full article, register now.